Quality of Life (QoL) in schizophrenia patients on Abilify Maintena (Aripiprazole) versus treatment with other atypical anti-psychotics (oral or depot) in a private mental health setting: a pilot randomized controlled trial.
Phase of Trial: Phase IV
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 20 Mar 2018 Planned End Date changed from 30 Sep 2018 to 31 Dec 2018.
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 09 Feb 2017 New trial record